Seeking Alpha

Mylan (MYL +0.5%) says the FDA has approved its Rizatriptan benzoate tablets - a generic version...

Mylan (MYL +0.5%) says the FDA has approved its Rizatriptan benzoate tablets - a generic version of Merck's (MRK) Maxalt tablets - for the treatment of migraine headaches in adults.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector